{"id":750629,"date":"2023-04-25T02:03:14","date_gmt":"2023-04-25T06:03:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/"},"modified":"2023-04-25T02:03:14","modified_gmt":"2023-04-25T06:03:14","slug":"verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/","title":{"rendered":"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LONDON and RALEIGH, N.C., April  25, 2023  (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT \/ 2:00 p.m. BST to discuss these financial results and provide a corporate update.<\/p>\n<p align=\"justify\">To participate, please dial one of the following numbers and ask to join the Verona Pharma call:<\/p>\n<ul type=\"disc\">\n<li style=\"text-align:justify\">+1-833-816-1396 for callers in the United States<\/li>\n<li style=\"margin-bottom:6pt;text-align:justify\">+1-412-317-0489 for international callers<\/li>\n<\/ul>\n<p align=\"justify\">A live webcast will be available on the Events and Presentations link on the Investors page of the Company\u2019s website, <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qUIgOw_TGHTzZ0SbaQEgcB9Ol6hkmx8GHEaJMpRkR7SOu9Lbazur1HhtK9449xcr3coQbFxtAyjp_PnMv6Ei3Vlt0pOQd5TGOkUHC6BdIJc=\" rel=\"nofollow noopener\" target=\"_blank\">www.veronapharma.com<\/a>, and the audio replay will be available for 90 days.<\/p>\n<p>For further information please contact:<\/p>\n<table style=\"border-collapse: collapse;margin-left:0px;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">\n            <strong>Verona Pharma plc<\/strong>\n          <\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">US Tel: +1-833-417-0262<br \/>UK Tel: +44 (0)203 283 4200<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">\u00a0<\/td>\n<td style=\"max-width:50%;width:50%;min-width:50%;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Victoria Stewart, Senior Director of Investor Relations and Communications<\/td>\n<td style=\"vertical-align: top\">\n            <a href=\"mailto:IR@veronapharma.com\" rel=\"nofollow noopener\" target=\"_blank\"><br \/>\n              <u>I<\/u><br \/>\n              <u>R<\/u><br \/>\n              <u>@veronapharma.com<\/u><br \/>\n            <\/a>\n          <\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Argot Partners<\/strong><br \/>\n            <br \/> (US Investor Enquiries)<\/td>\n<td style=\"vertical-align: top\">Tel: +1-212-600-1902<br \/><a href=\"mailto:verona@argotpartners.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>verona@argotpartners.com<\/u><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">\n            <strong>Optimum Strategic Communications<\/strong><br \/>\n            <br \/> (International Media and European Investor Enquiries)<\/td>\n<td style=\"vertical-align: top\">Tel: +44 (0)203 882 9621<br \/><a href=\"mailto:verona@optimumcomms.com\" rel=\"nofollow noopener\" target=\"_blank\"><u>verona@optimumcomms.com<\/u><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: top\">Mary Clark \/ Richard Staines \/ Zoe Bolt<\/td>\n<td style=\"vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0<\/td>\n<td style=\"vertical-align: middle;text-align: left;padding-left: 10.0px;vertical-align: top\">\u00a0<\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>About Verona Pharma<\/strong>\n      <\/p>\n<p align=\"justify\">Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of chronic respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma\u2019s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company has evaluated nebulized ensifentrine in its Phase 3 clinical program ENHANCE (\u201cEnsifentrine as a Novel inHAled Nebulized COPD thErapy\u201d) for COPD maintenance treatment. Ensifentrine met the primary endpoint in both ENHANCE-1 and ENHANCE-2 trials demonstrating statistically significant and clinically meaningful improvements in lung function. In addition, ensifentrine significantly reduced the rate and risk of COPD exacerbations in pooled analysis from ENHANCE-1 and ENHANCE-2. Two additional formulations of ensifentrine have been evaluated in Phase 2 studies for the treatment of COPD: dry powder inhaler (\u201cDPI\u201d) and pressurized metered-dose inhaler (\u201cpMDI\u201d). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=qUIgOw_TGHTzZ0SbaQEgcCJmKqBvwL2XWMN850VP3faHuQr3EziVz3vsP-0oITlAOaLfYQv669d3HjaNNeBn8Xo8kfHt0FQynTzSo5AdMEs=\" rel=\"nofollow noopener\" target=\"_blank\">www.veronapharma.com<\/a>.<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NTQxM2YxMzktOTU1ZS00M2ZmLTg3Y2ItYWI4ZjM3YWZlYmNmLTEwOTU5MzE=\/tiny\/Verona-Pharma-plc.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT \/ 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States +1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-750629","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT \/ 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States +1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the &hellip; Continue reading &quot;Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-25T06:03:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update\",\"datePublished\":\"2023-04-25T06:03:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/\"},\"wordCount\":376,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/\",\"name\":\"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=\",\"datePublished\":\"2023-04-25T06:03:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/","og_locale":"en_US","og_type":"article","og_title":"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update - Market Newsdesk","og_description":"LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) &#8212; Verona Pharma plc (Nasdaq: VRNA) (\u201cVerona Pharma\u201d or the \u201cCompany\u201d), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT \/ 2:00 p.m. BST to discuss these financial results and provide a corporate update. To participate, please dial one of the following numbers and ask to join the Verona Pharma call: +1-833-816-1396 for callers in the United States +1-412-317-0489 for international callers A live webcast will be available on the Events and Presentations link on the Investors page of the &hellip; Continue reading \"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-25T06:03:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update","datePublished":"2023-04-25T06:03:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/"},"wordCount":376,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/","name":"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=","datePublished":"2023-04-25T06:03:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyNDAzMiM1NTUyOTE3IzIwODQzNjA="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/verona-pharma-to-report-first-quarter-2023-financial-results-and-provide-corporate-update\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=750629"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/750629\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=750629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=750629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=750629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}